News about "Novartis"

Novartis Secures European Commission Approval for Itvisma in SMA

The European Commission (EC) has approved Novartis' Itvisma, the first gene replacement therapy in the European Union (EU) for a broad population with spinal muscular atrophy (SMA), including children, adolescents, and adults.

Novartis | 03/07/2026 | By News Bureau

Del-Brax from Novartis Achieves Primary Biomarker Endpoint in FSHD Study

Novartis reported positive phase 1/2 FORTITUDE study results for delpacibart braxlosiran (del-brax) in FSHD, meeting primary and key secondary biomarker endpoints. The therapy could become the first disease-modifying treatment for FSHD, with a phase 3 trial underway.

Novartis | 12/06/2026 | By News Bureau

Novartis Reports Strong Long-Term Efficacy of Scemblix in Chronic Myeloid Leukemia Trial

Novartis’ Scemblix demonstrated sustained efficacy and a favourable safety profile over nearly three years of follow-up, reinforcing its potential as a frontline treatment option for adults with Philadelphia chromosome-positive chronic myeloid leukemia.

Novartis | 03/06/2026 | By News Bureau

Novartis Expands US Manufacturing and R&D with Seventh Facility

Novartis advances its US expansion plan with a seventh facility, including a new API site in North Carolina to enable end-to-end manufacturing and accelerate delivery of innovative medicines.

Novartis | 04/05/2026 | By News Bureau |  139

Novartis Secures EC Approval for First Oral Targeted CSU Drug Rhapsido

Novartis introduces Rhapsido in Europe, offering a first-of-its-kind oral targeted therapy for patients with chronic spontaneous urticaria.

Novartis | 28/04/2026 | By News Bureau |  135

Novartis Signs Deal with Synnovation Therapeutics to Explore Next-Gen Breast Cancer Treatment

Novartis has signed a deal with Synnovation Therapeutics to advance SNV4818, a next-generation PI3Kα inhibitor in phase-I/II trials, targeting HR+/HER2- breast cancer patients with PIK3CA mutations, addressing a significant unmet need.

Novartis | 20/03/2026 | By News Bureau

US FDA Approves Novartis' Cosentyx for Adolescents with Moderate-to-Severe Hidradenitis Suppurativa

The FDA has approved Novartis’ Cosentyx for patients aged 12 years and above with moderate-to-severe Hidradenitis Suppurativa (HS), marking the therapy’s fourth paediatric indication and expanding treatment options with a differentiated IL-17A mechanism.

Novartis | 16/03/2026 | By News Bureau |  145

Novartis' Remibrutinib Shows Positive Phase III Results in Chronic Inducible Urticaria

Pivotal RemIND trial meets primary endpoint across three major CIndU subtypes, positioning oral remibrutinib as a potential first targeted therapy for inducible chronic hives.

Novartis | 19/02/2026 | By News Bureau |  402

Novartis Builds Global Biomedical Research Centre in San Diego

Novartis launches construction of a 466,000-square-foot biomedical research centre in San Diego, set to open in 2029, strengthening global drug discovery and advancing neuroscience, oncology and next-generation therapies.

Novartis | 09/02/2026 | By News Bureau |  143

Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026

Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.

Novartis | 05/02/2026 | By Darshana |  810